Search results for "Harm"

showing 10 items of 13866 documents

Common Hits Approach: Combining Pharmacophore Modeling and Molecular Dynamics Simulations.

2017

We present a new approach that incorporates flexibility based on extensive MD simulations of protein-ligand complexes into structure-based pharmacophore modeling and virtual screening. The approach uses the multiple coordinate sets saved during the MD simulations and generates for each frame a pharmacophore model. Pharmacophore models with the same pharmacophore features are pooled. In this way the high number of pharmacophore models that results from the MD simulation is reduced to only a few hundred representative pharmacophore models. Virtual screening runs are performed with every representative pharmacophore model; the screening results are combined and rescored to generate a single hi…

0301 basic medicineGeneral Chemical EngineeringDrug Evaluation PreclinicalLibrary and Information SciencesMolecular Dynamics Simulationcomputer.software_genreLigandsLigandScoutCommon Hits Approach (CHA)03 medical and health sciencesMolecular dynamicsUser-Computer InterfaceComputational chemistryPharmacophore ModelingFlexibility (engineering)Virtual screeningChemistryFrame (networking)ProteinsGeneral ChemistryInto-structureSettore CHIM/08 - Chimica FarmaceuticaComputer Science Applications030104 developmental biologyData miningPharmacophorecomputerJournal of chemical information and modeling
researchProduct

Evolution of the immune system influences speciation rates in teleost fishes.

2016

Teleost fishes constitute the most species-rich vertebrate clade and exhibit extensive genetic and phenotypic variation, including diverse immune defense strategies. The genomic basis of a particularly aberrant strategy is exemplified by Atlantic cod, in which a loss of major histocompatibility complex (MHC) II functionality coincides with a marked expansion of MHC I genes. Through low-coverage genome sequencing (9–39×), assembly and comparative analyses for 66 teleost species, we show here that MHC II is missing in the entire Gadiformes lineage and thus was lost once in their common ancestor. In contrast, we find that MHC I gene expansions have occurred multiple times, both inside and outs…

0301 basic medicineGenetic SpeciationLineage (evolution)Adaptation BiologicalGene Dosagechemical and pharmacologic phenomenaMajor histocompatibility complexMajor Histocompatibility Complex03 medical and health sciencesSpecies Specificitybiology.animalMHC class IGeneticsAnimals14. Life underwaterCladePhylogenyGeneticsGenomebiologyFishesVertebrateAcquired immune systemBiological Evolution030104 developmental biologyGenetic SpeciationImmune Systembiology.proteinAdaptationNature genetics
researchProduct

Genetics and Gene Therapy of Anderson-Fabry Disease.

2018

Fabry's disease is a genetic disorder of X-linked inheritance caused by mutations in the alpha galactosidase A gene resulting in deficiency of this lysosomal enzyme. The progressive accumulation of glycosphingolipids, caused by the inadequate enzymatic activity, is responsible of organ dysfunction and thus of clinical manifestations. In the presence of a high clinical suspicion, a careful physical examination and specific laboratory tests are required, finally diagnosis of Fabry's disease is confirmed by the demonstration of absence or reduced alpha-galactosidase A enzyme activity in hemizygous men and gene typing in heterozygous females; in fact the performance of enzymatic activity assay …

0301 basic medicineGenetic enhancementChaperone therapyDisease030204 cardiovascular system & hematologyBioinformaticsMice0302 clinical medicineAlpha galactosidase ADrug DiscoveryGenetics (clinical)KidneybiologyTrihexosylceramidesGenetic disorderEnzyme replacement therapyDependovirusRecombinant ProteinsAlpha galactosidase A; Chaperone therapy; Enzyme replacement therapy; Fabry disease; Gene therapy; Viral vectors; Molecular Medicine; Molecular Biology; Genetics; Drug Discovery3003 Pharmaceutical Science; Genetics (clinical)Isoenzymesmedicine.anatomical_structureMolecular Medicinemedicine.symptomGenetic Vectors03 medical and health sciencesGene therapyViral vectorRare DiseasesGeneticGeneticsmedicineAnimalsHumansEnzyme Replacement TherapyMolecular BiologyAlpha-galactosidasebusiness.industryDrug Discovery3003 Pharmaceutical ScienceOrgan dysfunctionGenetic Therapymedicine.diseaseFabry diseaseDisease Models Animal030104 developmental biologyalpha-GalactosidaseMutationbiology.proteinFabry DiseasebusinessBiomarkersCurrent gene therapy
researchProduct

Regulatory T Cells in an Endogenous Mouse Lymphoma Recognize Specific Antigen Peptides and Contribute to Immune Escape.

2019

Abstract Foxp3+ regulatory T cells (Tregs) sustain immune homeostasis and may contribute to immune escape in malignant disease. As a prerequisite for developing immunologic approaches in cancer therapy, it is necessary to understand the ontogeny and the antigenic specificities of tumor-infiltrating Tregs. We addressed this question by using a λ-MYC transgenic mouse model of endogenously arising B-cell lymphoma, which mirrors key features of human Burkitt lymphoma. We show that Foxp3+ Tregs suppress antitumor responses in endogenous lymphoma. Ablation of Foxp3+ Tregs significantly delayed tumor development. The ratio of Treg to effector T cells was elevated in growing tumors, which could be …

0301 basic medicineGenetically modified mouseCancer ResearchLymphoma B-CellImmunologychemical and pharmacologic phenomenaMice TransgenicT-Lymphocytes RegulatoryEpitope03 medical and health sciences0302 clinical medicineAntigenCell Line TumorMHC class ImedicineAnimalsAntigensbiologyEffectorFOXP3hemic and immune systemsmedicine.diseaseLymphomaMice Inbred C57BL030104 developmental biologyTumor Escape030220 oncology & carcinogenesisCancer researchbiology.proteinTumor EscapePeptidesCancer immunology research
researchProduct

Atypical 1,4-dihydropyridine derivatives, an approach to neuroprotection and memory enhancement

2016

This mini review is devoted to the design and pharmacological studies of novel atypical 1,4-dihydropyridine (DHP) derivatives which differ to a great extent from the traditional DHPs either by lack of neuronal calcium channel blocking activity and/or inability to protect mitochondrial processes. About 100 new DHP derivatives were screened and the mostly active were selected for detailed studies. The compounds of the series of the amino acid ("free" plus "crypto")-containing DHPs and lipophilic di-cyclic DHPs demonstrated long-lasting neuroprotective and/or memory-enhancing action, particularly at low doses (0.005-0.05mg/kg) in different neurodeficiency rat or mice models, and exerted neurot…

0301 basic medicineGenetically modified mouseDihydropyridinesDHPSNeurotransmissionBiologyPharmacologyNeuroprotection03 medical and health sciences0302 clinical medicineMemoryAnimalsHumansPharmacologychemistry.chemical_classificationNeurotransmitter AgentsCalcium channelCalcium Channel BlockersNeuroprotectionAmino acid030104 developmental biologychemistrySynaptic plasticityNervous System DiseasesNeurotransmitter AgentsNeuroscience030217 neurology & neurosurgeryPharmacological Research
researchProduct

Behavioral fragmentation in the D1CT-7 mouse model of Tourette's syndrome.

2017

Aim The transgenic D1CT-7 mouse is one of the best-characterized animal models of Tourette's syndrome (TS), exhibiting spontaneous tic-like Head-Body Twitches (HBT) and deficits in sensorimotor gating. This study is aimed at evaluating the behavioral dynamics of these mutants and their potential relevance to TS. Methods The behavior of D1CT-7 and Wild Type littermates was firstly assessed by considering frequencies and durations. To detect recurrent real-time behavioral sequences, the multivariate T-pattern analysis was employed. Analyses of transition probabilities among behaviors further provided an overall picture of the behavioral dynamics. Results T-patterns and transition matrices rev…

0301 basic medicineGenetically modified mouseMaleCholera ToxinTransgeneTourette's syndromeMice Transgenictransition matriceBiologyMotor ActivityTourette syndromeOpen fieldStatistics Nonparametric03 medical and health sciencesMice0302 clinical medicineSniffingPhysiology (medical)medicineAnimalsPharmacology (medical)tic disorderGait Disorders NeurologicPharmacologyMice Inbred BALB CD1CT-7Behavior AnimalReceptors Dopamine D1Wild typeBehavioral patternT-pattern analysiOriginal Articlesmedicine.diseasePhenotypeDisease Models Animal030104 developmental biologyPsychiatry and Mental HealthMotor SkillsExploratory BehaviorNeuroscience030217 neurology & neurosurgeryTourette SyndromeCNS neurosciencetherapeutics
researchProduct

BNT162b2 Vaccine Encoding the SARS-CoV-2 P2 S Protects Transgenic hACE2 Mice against COVID-19.

2021

BNT162b2 is a highly efficacious mRNA vaccine approved to prevent COVID-19. This brief report describes the immunogenicity and anti-viral protective effect of BNT162b2 in hACE2 transgenic mice. Prime-boost immunization with BNT162b2 elicited high titers in neutralizing antibodies against SARS-CoV-2, which correlated with viral clearance and alleviated lung lesions in these mice after viral challenge.

0301 basic medicineGenetically modified mouseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)TransgenevirusesImmunologyefficacylcsh:Medicineimmunogenicitychallenge study03 medical and health sciences0302 clinical medicineDrug DiscoveryMedicinePharmacology (medical)030212 general & internal medicinePharmacologyMessenger RNAbiologybusiness.industrySARS-CoV-2Brief ReportImmunogenicitylcsh:RCOVID-19VirologyTiter030104 developmental biologyInfectious DiseasesmRNA vaccineImmunizationbiology.proteinAntibodybusinessVaccines
researchProduct

miR-22 suppresses DNA ligase III addiction in multiple myeloma

2019

Multiple myeloma (MM) is a hematologic malignancy characterized by high genomic instability. Here we provide evidence that hyper-activation of DNA ligase III (LIG3) is crucial for genomic instability and survival of MM cells. LIG3 mRNA expression in MM patients correlates with shorter survival and even increases with more advanced stage of disease. Knockdown of LIG3 impairs MM cells viability in vitro and in vivo, suggesting that neoplastic plasmacells are dependent on LIG3-driven repair. To investigate the mechanisms involved in LIG3 expression, we investigated the post-transcriptional regulation. We identified miR-22-3p as effective negative regulator of LIG3 in MM. Enforced expression of…

0301 basic medicineGenome instabilityCancer ResearchmiR-22 LIG3DNA repairDNA damageDNA repairApoptosisLIG3ArticleDNA Ligase ATP03 medical and health sciences0302 clinical medicinemicroRNABiomarkers TumorTumor Cells CulturedHumansPoly-ADP-Ribose Binding ProteinsCell ProliferationmiRNAchemistry.chemical_classificationRegulation of gene expressionGene knockdownDNA ligaseLeukemiamicroRNAChemistryHematologyPrognosisXenograft Model Antitumor AssaysGene Expression Regulation Neoplasticmultiple myelomaMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisCancer researchpharmacologyDNA DamageLeukemia
researchProduct

Artemisinin Derivatives Target Topoisomerase 1 and Cause DNA Damage in Silico and in Vitro

2017

DNA topoisomerases 1 and 2 are enzymes that maintain DNA topology and play important essential genome functions, including DNA replication and transcription. Aberrant topoisomerases cause genome instability and a wide range of diseases, cancer in particular. Both Topo 1 and 2 are the targets of valuable anticancer drugs, such as camptothecin. It has been previously shown that artemisinin, a sesquiterpene lactone from Artemisia annua L. also known as qinghaosu, possesses anti-cancer effects and one of its derivatives, artesunate inhibits Topo 2. In this study, we evaluated artemisinin and 40 derivatives as potential Topo 1 inhibitors at first by in silico molecular docking analyses. Five com…

0301 basic medicineGenome instabilityDNA damageArtemisia annua03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicinecancerPharmacology (medical)Original ResearchPharmacologytopoisomerasebiologyTopoisomeraselcsh:RM1-950DNA replicationmolecular dockingbiology.organism_classificationMolecular biologyComet assaylcsh:Therapeutics. Pharmacology030104 developmental biologychemistryartemisinin030220 oncology & carcinogenesisbiology.proteinDNA damageCamptothecinDNAmedicine.drugFrontiers in Pharmacology
researchProduct

Viral resistance in HCV infection.

2018

The introduction of new multi-genotypic direct acting antivirals (DAA) in clinical practice has revolutionized HCV treatment, permitting the achievement of >95% rates of sustained virological response in many patients. However, virological failures can occur particularly if the treatments are sub optimal and/or with too short duration. Failure is often associated with development of resistance. The wide genetic variability in terms of different genotypes and subtypes, together with the natural presence and/or easy development of resistance during treatment, are intrinsic characteristics of HCV that may affect the treatment outcome and the chances of achieving a virological cure. This review…

0301 basic medicineGenotypeTreatment outcomeDrug ResistanceDrug resistanceHepacivirusBiologyViral resistanceAntiviral AgentsVirological response03 medical and health sciences0302 clinical medicinePharmacotherapyDrug TherapyDrug Resistance Multiple ViralVirologyRibavirinmedicineHumansGenetic variabilityViralTreatment FailureChronicAntiviral Agents; Drug Therapy Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferons; Ribavirin; Treatment Failure; Drug Resistance Multiple ViralGenetic VariationHepatitis CHepatitis C Chronicmedicine.diseaseSettore MED/07 - Microbiologia e Microbiologia ClinicaHepatitis C030104 developmental biologyHCVImmunologyCombinationHcv treatment030211 gastroenterology & hepatologyDrug Therapy CombinationInterferonsMultipleCurrent opinion in virology
researchProduct